Semaglutide

Semagultide, sold under the brand names Wegovy or Ozempic, works like the body’s own hormone to regulate the blood sugar (glucose) level and appetite. Researchers have tested Semaglutide in more than 5000 people.

Semaglutide also decreases “gastric emptying,” the process by which stomach contents are moved into the first part of the small intestine as part of the digestive process.

Semaglutide injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:

Adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

Pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity).

** A 2 -month commitment is mandatory for all memberships**